Business Context and Reporting Period
This Form 8-K Current Report was filed by Bruker Corporation on January 16, 2025. The filing discloses a corporate governance event under Item 5.02 regarding the appointment of a new senior officer.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to executive compensation:
- Annual Base Salary: $415,000.04
- Incentive Bonus Eligibility: 45% of base salary
- Equity Grant: 2,972 Restricted Stock Units (RSUs)
Material Changes
On January 13, 2025, Thomas Bures was appointed as the Chief Accounting Officer, effective immediately. This appointment represents a change in the Company's senior management team.
Outlook, Risks, and Management Commentary
Management Commentary: Mr. Bures brings over 20 years of finance experience, primarily in the healthcare and life sciences sectors. His recent roles include Senior Vice President and CFO of Pieris Pharmaceuticals and Vice President and Corporate Controller of Genocea Biosciences Inc.
Compensation Structure: The RSU grant is scheduled to vest ratably at 25% per year over four years, commencing on the first anniversary of the grant date (approximately February 15, 2025).
Risks and Contingencies: The filing states there are no other arrangements or understandings regarding Mr. Bures' selection, no family relationships with other officers or directors, and no material interests in transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the vesting schedule and performance conditions of the 2,972 RSUs granted to the new Chief Accounting Officer.
- Review the Company's 2016 Incentive Compensation Plan (referenced in the filing) for details on the RSU agreement terms.
- Confirm the effective date of the appointment (January 13, 2025) against internal corporate records.
- Note that this filing contains no operational or financial results; refer to the most recent 10-K or 10-Q for financial metrics.